基因融合-话题@MedSci

#基因融合#

20篇内容 | 753人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2197485, encodeId=f7ba219e485af, content=<a href='/topic/show?id=4c239032154' target=_blank style='color:#2F92EE;'>#衰老#</a> <a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a> <a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>, objectTitle=PNAS：AML衰老和综合分子图谱成功构建，揭示老年患者的基因融合减少而基因突变增加, objectType=article, longId=820483, objectId=46de8204835d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=46de8204835d, replyNumber=0, likeNumber=14, createdTime=2024-04-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=46de8204835d, moduleTitle=PNAS：AML衰老和综合分子图谱成功构建，揭示老年患者的基因融合减少而基因突变增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46de8204835d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1668431, encodeId=b2bc1668431b4, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格” , objectType=article, longId=205518, objectId=dfc82055184d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc82055184d, replyNumber=0, likeNumber=44, createdTime=2021-05-01, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc82055184d, moduleTitle=FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格” , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc82055184d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668430, encodeId=9c4916684302a, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=ARCH PATHOL LAB MED：用于同时检测癌症基因组中单核苷酸变异、插入/缺失、拷贝数改变和基因融合的靶向测序平台的性能特征, objectType=article, longId=203961, objectId=21bc20396187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21bc20396187, replyNumber=0, likeNumber=41, createdTime=2020-12-15, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21bc20396187, moduleTitle=ARCH PATHOL LAB MED：用于同时检测癌症基因组中单核苷酸变异、插入/缺失、拷贝数改变和基因融合的靶向测序平台的性能特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21bc20396187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668428, encodeId=a1af166842885, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤, objectType=article, longId=196520, objectId=4e2c19652009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2c19652009, replyNumber=0, likeNumber=42, createdTime=2020-10-22, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2c19652009, moduleTitle=又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2c19652009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668426, encodeId=2b481668426fc, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤, objectType=article, longId=192797, objectId=6bd8192e9745, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bd8192e9745, replyNumber=0, likeNumber=39, createdTime=2021-02-14, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bd8192e9745, moduleTitle=英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bd8192e9745)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668429, encodeId=87141668429da, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准, objectType=article, longId=198676, objectId=870a1986e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870a1986e628, replyNumber=0, likeNumber=62, createdTime=2020-09-29, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870a1986e628, moduleTitle=Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=870a1986e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668427, encodeId=8919166842e27, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=NTRK基因融合性肿瘤的治疗：larotrectinib即将在日本上市, objectType=article, longId=194691, objectId=1a6f1946914b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a6f1946914b, replyNumber=0, likeNumber=32, createdTime=2020-11-06, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a6f1946914b, moduleTitle=NTRK基因融合性肿瘤的治疗：larotrectinib即将在日本上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a6f1946914b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668425, encodeId=53401668425c2, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=Clin Chem：突破！RNA+DNA同时测序，检测癌症组织中的基因融合和碱基突变！, objectType=article, longId=184591, objectId=fa6318459181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa6318459181, replyNumber=0, likeNumber=33, createdTime=2020-05-01, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa6318459181, moduleTitle=Clin Chem：突破！RNA+DNA同时测序，检测癌症组织中的基因融合和碱基突变！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa6318459181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668423, encodeId=da2316684236c, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=Xp11.2易位/TFE3基因融合相关性肾癌1例, objectType=article, longId=179854, objectId=4f771e985478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f771e985478, replyNumber=0, likeNumber=41, createdTime=2020-01-25, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f771e985478, moduleTitle=Xp11.2易位/TFE3基因融合相关性肾癌1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f771e985478)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668424, encodeId=e1fa1668424fe, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=拜耳TRK抑制剂Vitrakvi获得欧盟批准治疗NTRK基因融合的肿瘤患者, objectType=article, longId=180106, objectId=b99c180106aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b99c180106aa, replyNumber=0, likeNumber=35, createdTime=2020-09-04, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b99c180106aa, moduleTitle=拜耳TRK抑制剂Vitrakvi获得欧盟批准治疗NTRK基因融合的肿瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b99c180106aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668419, encodeId=78ff1668419ee, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=泛癌种靶向药在日本获批用于治疗NTRK基因融合晚期复发实体瘤, objectType=article, longId=168843, objectId=cbc71688433a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbc71688433a, replyNumber=0, likeNumber=40, createdTime=2019-07-02, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbc71688433a, moduleTitle=泛癌种靶向药在日本获批用于治疗NTRK基因融合晚期复发实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbc71688433a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668422, encodeId=b4d016684220e, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, objectType=article, longId=177801, objectId=78401e780141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78401e780141, replyNumber=0, likeNumber=29, createdTime=2020-05-07, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78401e780141, moduleTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78401e780141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668418, encodeId=526116684185c, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=拜耳公布larotrectinib治疗NTRK基因融合阳性转移性非小细胞肺癌患者的亚组分析结果, objectType=article, longId=164175, objectId=36571641e5d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36571641e5d2, replyNumber=0, likeNumber=33, createdTime=2019-06-06, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36571641e5d2, moduleTitle=拜耳公布larotrectinib治疗NTRK基因融合阳性转移性非小细胞肺癌患者的亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36571641e5d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668421, encodeId=bafb1668421f4, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=加拿大卫生部批准VITRAKVI®（larotrectinib）治疗NTRK基因融合的晚期实体瘤, objectType=article, longId=176548, objectId=f7e11e654865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7e11e654865, replyNumber=0, likeNumber=38, createdTime=2020-03-20, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7e11e654865, moduleTitle=加拿大卫生部批准VITRAKVI®（larotrectinib）治疗NTRK基因融合的晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7e11e654865)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668420, encodeId=66e8166842042, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=EMA建议批准Vitrakvi治疗NTRK基因融合的实体瘤患者, objectType=article, longId=176376, objectId=d5511e6376a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5511e6376a5, replyNumber=0, likeNumber=31, createdTime=2019-10-09, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5511e6376a5, moduleTitle=EMA建议批准Vitrakvi治疗NTRK基因融合的实体瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5511e6376a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668416, encodeId=bb9a16684165e, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=Cancer Lett：TMPRSS2:ERG基因融合表达能够调控骨标记和增强前列腺癌骨转移成骨细胞表型, objectType=article, longId=149110, objectId=c33914911057, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c33914911057, replyNumber=0, likeNumber=28, createdTime=2019-05-30, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c33914911057, moduleTitle=Cancer Lett：TMPRSS2:ERG基因融合表达能够调控骨标记和增强前列腺癌骨转移成骨细胞表型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c33914911057)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668417, encodeId=78fc166841e68, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=罗氏的entrectinib获得FDA的快速审查用于治疗NTRK基因融合肿瘤, objectType=article, longId=160643, objectId=df3616064305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df3616064305, replyNumber=0, likeNumber=35, createdTime=2019-11-18, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df3616064305, moduleTitle=罗氏的entrectinib获得FDA的快速审查用于治疗NTRK基因融合肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df3616064305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668415, encodeId=87c0166841578, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=Nature：基因融合下游致癌信号被揭示, objectType=article, longId=125593, objectId=201d12559356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=201d12559356, replyNumber=0, likeNumber=39, createdTime=2018-07-16, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=201d12559356, moduleTitle=Nature：基因融合下游致癌信号被揭示, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=201d12559356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668414, encodeId=b0b9166841499, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=EGFR基因突变/ALK基因融合阳性肺鳞癌的靶向治疗, objectType=article, longId=107808, objectId=dadd10e80888, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dadd10e80888, replyNumber=0, likeNumber=43, createdTime=2017-11-19, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dadd10e80888, moduleTitle=EGFR基因突变/ALK基因融合阳性肺鳞癌的靶向治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dadd10e80888)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1668413, encodeId=1d501668413d3, content=<a href='/topic/show?id=fcde4188421' target=_blank style='color:#2F92EE;'>#基因融合#</a>, objectTitle=Science：转化性FGFR-TACC基因融合引发恶性胶质母细胞瘤, objectType=article, longId=8275, objectId=6f5a82e5e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f5a82e5e3, replyNumber=0, likeNumber=40, createdTime=2013-03-25, rootId=0, userName=lvygwyt2790, userId=b07026292028, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f5a82e5e3, moduleTitle=Science：转化性FGFR-TACC基因融合引发恶性胶质母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f5a82e5e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

基因融合

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#衰老# #基因融合# #AML#

PNAS：AML衰老和综合分子图谱成功构建，揭示老年患者的基因融合减少而基因突变增加

2024-04-08发表于陕西省

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格”

2021-05-01

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

ARCH PATHOL LAB MED：用于同时检测癌症基因组中单核苷酸变异、插入/缺失、拷贝数改变和基因融合的靶向测序平台的性能特征

2020-12-15

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤

2020-10-22

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤

2021-02-14

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准

2020-09-29

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

NTRK基因融合性肿瘤的治疗：larotrectinib即将在日本上市

2020-11-06

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

Clin Chem：突破！RNA+DNA同时测序，检测癌症组织中的基因融合和碱基突变！

2020-05-01

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

Xp11.2易位/TFE3基因融合相关性肾癌1例

2020-01-25

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

拜耳TRK抑制剂Vitrakvi获得欧盟批准治疗NTRK基因融合的肿瘤患者

2020-09-04

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

泛癌种靶向药在日本获批用于治疗NTRK基因融合晚期复发实体瘤

2019-07-02

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC

2020-05-07

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

拜耳公布larotrectinib治疗NTRK基因融合阳性转移性非小细胞肺癌患者的亚组分析结果

2019-06-06

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

加拿大卫生部批准VITRAKVI®（larotrectinib）治疗NTRK基因融合的晚期实体瘤

2020-03-20

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

EMA建议批准Vitrakvi治疗NTRK基因融合的实体瘤患者

2019-10-09

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

Cancer Lett：TMPRSS2:ERG基因融合表达能够调控骨标记和增强前列腺癌骨转移成骨细胞表型

2019-05-30

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

罗氏的entrectinib获得FDA的快速审查用于治疗NTRK基因融合肿瘤

2019-11-18

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

Nature：基因融合下游致癌信号被揭示

2018-07-16

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

EGFR基因突变/ALK基因融合阳性肺鳞癌的靶向治疗

2017-11-19

lvygwyt2790 (审核中...)

前往app查看评论内容

#基因融合#

Science：转化性FGFR-TACC基因融合引发恶性胶质母细胞瘤

2013-03-25

科室
- - 订阅+
  - 更多科室
工具
服务